La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Intensity Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Intensity Therapeutics..

Intensity Therapeutics (NASDAQ:INTS) Azioni, Catena delle Opzioni

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

News

Dividends

F&G Annuities & Life Increases Quarterly Dividend From $0.21 To $0.22/Share

<p><strong>Fiscal 2024 Outlook</strong></p>
<p>Thilo Wrede, Vital Farms' Chief Financial Officer, commented: "With another solid performance in the third quarter, I am pleased to again update our guidance for 2024. Our new outlook reflects the strong performance of the business for the first nine months of this year and our good visibility for the fourth quarter of 2024. Our revised guidance is built around a favorable commodity outlook and strong consumer demand supported by our marketing reinvestment strategy. Vital Farms' long-term strategy is built to increase brand awareness, drive deeper loyalty with consumers, and grow our household penetration through focused energies on brand marketing and continuous retail expansion."</p>
<p>For the fiscal year 2024, management now expects:</p>
<ul>
<li>Net revenue of at least $600 million, which represents at least 27% growth versus fiscal year 2023, compared to our previous expectation of at least $590 million, or 25% growth.</li>
<li>Adjusted EBITDA of at least $80 million, which represents at least 65% growth versus fiscal year 2023, compared to our previous expectation of at least $75 million, or 55% growth.</li>
<li>Capital expenditures for the full year in the range of $30 million to $40 million, which is reduced from our previous range of $35 million to $45 million due to updated timing on some key projects. We continue to evaluate our capital allocation priorities, and we will provide updates as necessary in future earnings reports.<br /><br />&nbsp;</li>
</ul>
<p>Vital Farms' guidance includes the effect of lapping an extra shipping week in Q4 2023 and assumes that there are no significant disruptions to the supply chain or its customers or consumers, including any issues from adverse macroeconomic factors. Vital Farms cannot provide a reconciliation between its forecasted Adjusted EBITDA and net income and Adjusted EBITDA Margin and net income margin, their most directly comparable GAAP measures, without unreasonable effort due to the unavailability of reliable estimates for income taxes, among other items. These items are not within our control and may vary greatly between periods and could significantly impact future financial results.</p>


Guidance

VITL

Vital Farms Sees FY24 Revenue Of At least $600M Vs $598.35M Est.

<p><strong>Z: 15% &#x7C; </strong><a href="https://www.benzinga.com//node/41803768">Zillow Group shares are trading higher after the company reported better-than-expected Q3 financial results.</a></p>
<p>&nbsp;</p>
<p><strong>APP: 32% &#x7C; </strong><a href="https://www.benzinga.com//node/41803196">Applovin shares are trading higher after the company reported better-than-expected Q3 financial results.</a></p>
<p>&nbsp;</p>
<p><strong>CYN: 63% &#x7C; </strong><a href="https://www.benzinga.com//node/41803438">Cyngn Announced Progress Of Its Proprietary Computer Vision Technology For Industrial Autonomous Machines, Built On Nvidia Accelerated Computing</a></p>


Movers

Trading Ideas

Market-Moving News for November 7th

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) with a Buy and maintains $35 price target.</p>


Price Target

Reiteration

Analyst Ratings

ALEC

HC Wainwright & Co. Reiterates Buy on Alector, Maintains $35 Price Target

<p><strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) announced its Q3 earnings on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% drop share price change the next day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Competitors that recently released earnings</h3>
<p>When analyzing Clear Channel Outdoor's numbers, it's imperative to put them into context by comparing them to those of its competitors, like PubMatic, TechTarget, and National CineMedia.</p>
<ul>
<li>PubMatic announced strong earnings on August 08, 2024, surpassing market expectations. Despite an estimated EPS of $-0.02, PubMatic's actual EPS was $0.17, reflecting a 950.0% increase.</li>
<li>TechTarget's earnings announcement on August 08, 2024 exceeded expectations, with an actual EPS of $0.42 compared to the market's projected EPS of $0.4, resulting in a 5.0% increase.</li>
<li>National CineMedia reported earnings on November 05, 2024 that fell short of expectations, with an actual EPS of $-0.04 compared to the market's estimate of $-0.03, resulting in a -33.33% decrease.</li>
</ul>
<h3>Insights into Competitors' Quarterly Earnings and Stock Performance</h3>
<p>In this detailed analysis, insights are provided into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Comparative Assessment: Estimated in Comparison with Actual Peer Revenues</h3>
<p>The following table compares estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context to understand their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Clear Channel Outdoor: Q3 Earnings Insights

<p>Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.71) by 25.35 percent.  The company reported $416.000 thousand in sales this quarter. This is a 99.59 percent decrease over sales of $102.693 million the same period last year.</p>


Earnings Beats

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharma Q3 2024 Adj. EPS $(0.53) Beats $(0.71) Estimate, Sales $416.000K Down From $102.693M YoY

<p>Jefferies  analyst Julien Dumoulin-Smith   initiates coverage on Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) with a Buy rating and announces Price Target of $93.</p>


Initiation

Jefferies Initiates Coverage On Edison Intl with Buy Rating, Announces Price Target of $93

CING

Cingulate Q3 Net Loss $3.2M

Biotech

Health Care

Management

General

CALC

CalciMedica Has Appointed Stephen Bardin As Chief Financial Officer And The Planned Departure Of Daniel Geffken, Interim Chief Financial Officer Upon Filing The Company's Third Quarter Financial Statements

<p><strong>Reaffirms Full Year 2024 Outlook on Key Metrics</strong></p>
<p>The Company is reaffirming its full year 2024 outlook on Key Metrics:</p>
<ul>
<li><strong>Net sales </strong>to decrease low to high teens in percentage terms, tracking toward the middle of the range.</li>
<li><strong>Adjusted EBITDA</strong>(1) that is positive.</li>
<li><strong>Free Cash Flow</strong>(1) that is positive.<br /><br />&nbsp;</li>
</ul>
<p>Hydrofarm's 2024 outlook also reaffirms the following assumptions:</p>
<ul>
<li>Reduced year-over-year Adjusted SG&amp;A(1) expense resulting primarily from (i) full year benefit of headcount reductions completed in 2023 and (ii) reductions in professional fees, facilities and insurance expenses.</li>
<li>Reduction in inventory and net working capital helping to generate positive Free Cash Flow(1) for the full year.</li>
</ul>
<p>Hydrofarm's 2024 outlook also includes the following updated assumptions:</p>
<ul>
<li>Adjusted Gross Profit Margin(1) that is flat to slightly down compared to the prior year. This is an update to the prior expectation of a year-over-year improvement.</li>
<li>Capital expenditures of $2.5 million to $3.5 million, compared to the prior expectation of $3.5 million to $4.5 million.</li>
</ul>
<p><i>(1) Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted SG&amp;A, Adjusted SG&amp;A as a percent of net sales, Adjusted EBITDA, and Free Cash Flow are non-GAAP measures. For reconciliations of GAAP to non-GAAP measures see the "Reconciliation of Non-GAAP Measures" accompanying the release.</i></p>


HYFM

Hydrofarm Sees FY24 Net Sales To Decrease Low To High Teens In Percentage Terms, Tracking Toward The Middle Of The Range

<p>Wedbush  analyst Nick Setyan   reiterates Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Outperform and maintains $47 price target.</p>


Wedbush Reiterates Outperform on Dine Brands Global, Maintains $47 Price Target

<p>Kelly Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KELYB#NASDAQ">KELYB</a>) reported quarterly earnings of $0.21 per share. This is a 58 percent decrease over earnings of $0.50 per share from the same period last year.  The company reported $1.04 billion in sales this quarter. This is a 7.16 percent decrease over sales of $1.12 billion the same period last year.</p>


KELYB

Kelly Services Q3 EPS $0.21 Down From $0.50 YoY, Sales $1.04B Down From $1.12B YoY

NTLA

Intellia Ended The Third Quarter Of 2024 With Approximately $944.7M In Cash, Cash Equivalents And Marketable Securities, The Cash Position Is Expected To Fund Operations Into Late 2026

Altimmune Announces Completion Of End-of-Phase 2 Meeting With FDA For Pemvidutide In Obesity Treatment; Company And Agency Aligned On Key Efficacy And Safety Measures To Be Studied In Phase 3 Program

<p>Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.40) by 4.29 percent.</p>


Intellia Therapeutics Q3 2024 GAAP EPS $(1.34) Beats $(1.40) Estimate

<p>UBS  analyst Steven Fisher   initiates coverage on Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Buy rating and announces Price Target of $349.</p>


UBS Initiates Coverage On Vulcan Materials with Buy Rating, Announces Price Target of $349

<p>WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.41 by 3.9 percent. This is a 15.27 percent decrease over earnings of $0.47 per share from the same period last year.  The company reported quarterly sales of $22.851 million which missed the analyst consensus estimate of $23.203 million by 1.52 percent.  This is a 2.69 percent decrease over sales of $23.482 million the same period last year.</p>


Earnings Misses

WhiteHorse Finance Q3 2024 Adj. EPS $0.39 Misses $0.41 Estimate, Sales $22.851M Miss $23.203M Estimate

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $27 price target.</p>


ACAD

HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $27 Price Target

HOUS

Anywhere Real Estate Q3 2024 Adj. EPS $0.06 May Not Compare To $0.29 Estimate, Sales $1.535B Miss $1.624B Estimate

<p><strong>Fourth Quarter and 2024 Outlook</strong></p>
<p>The Company is reaffirming its fiscal year 2024 outlook of 4.5% to 5.5% revenue growth, based on year-to-date performance and current business trends. For the fourth quarter, the Company anticipates continued strong high single digit year-over-year growth in OEM &amp; National revenue, as well as modest growth in Dealer revenue.</p>
<p>Adjusted EBITDA margin outlook for fiscal 2024 remains 28.0% to 30.0%, reflecting disciplined cost management to continue delivering strong operating leverage for the remainder of the year.</p>


CARS

Cars.com Reaffirms FY24 Revenue Outlook 4.5%-5.5% Growth

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Intensity Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ints-stock-quote/"><strong>INTS</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Intensity Therapeutics reported earnings per share of -34 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/ints-stock-earnings-intensity-therapeutics-for-q1-of-2024/">INTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

INTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024

Intensity Therapeutics GAAP EPS of -$0.34

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

Intensity Therapeutics, Inc. (INTS) has shared an announcement. Intensity Therapeutics, Inc. has expanded its Board of Directors by appointing Thom...

Intensity Therapeutics Expands Board, Welcomes New Audit Director

Intensity Therapeutics files to sell common stock by selling stockholders

Intensity Therapeutics, Inc. (INTS) has provided an announcement. Intensity Therapeutics, Inc. successfully conducted its Annual Meeting via live w...

Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting

Intensity Therapeutics GAAP EPS of -$0.36

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Intensity Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ints-stock-quote/"><strong>INTS</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Intensity Therapeutics reported earnings per share of -36 cents. This was below the analyst estimate for EPS of -32 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/ints-stock-earnings-intensity-therapeutics-for-q2-of-2024/">INTS Stock Earnings: Intensity Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

INTS Stock Earnings: Intensity Therapeutics Misses EPS for Q2 2024

Intensity Therapeutics, Inc. (INTS) has received a new Buy rating, initiated by H.C. Wainwright analyst, Swayampakula Ramakanth. Swayampakula Ramak...

Innovative Cancer Treatment Approach Positions Intensity Therapeutics as a Compelling Investment Opportunity

Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research SAKK, a decentralized academic research institute that has been cond...

Intensity Therapeutics announces first dosing in Phase 2 trial of INT230-6

INTS

Press Releases

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Financing

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Comments

Intensity Therapeutics

Intensity Therapeutics (INTS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO